| Code | CSB-RA011587MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Ebdarokimab, designed for research applications targeting IL12B (interleukin-12 subunit beta), also known as IL-12p40. IL12B encodes a crucial subunit shared by both IL-12 and IL-23, two pro-inflammatory cytokines that play pivotal roles in immune regulation and T-cell differentiation. IL-12 promotes Th1 cell development and IFN-γ production, while IL-23 supports Th17 cell maintenance and function. Dysregulation of IL12B-related pathways has been implicated in numerous autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, inflammatory bowel disease, and Crohn's disease, making it a significant target for immunological research.
Ebdarokimab is a therapeutic monoclonal antibody that specifically binds to the p40 subunit, thereby neutralizing both IL-12 and IL-23 signaling pathways. This biosimilar antibody provides researchers with a valuable tool for investigating IL12B-mediated immune responses, studying cytokine network dynamics, and exploring therapeutic mechanisms in inflammatory disease models. It supports diverse immunology research applications, including cytokine neutralization studies and pathway analysis experiments.
There are currently no reviews for this product.